Farmako: World's Largest Import Contract for Pharmaceutical Cannabis


German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska

FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. 

  • This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP.
  • Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years.
  • Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored strains for European patients.
  • Farmako has been selling pharmaceutical cannabis to German pharmacies since March 2019 generating over 100k EUR revenue in the first week of operations.

Sebastian Diemer, Founder and Chairman of Farmako: ”This is a big leap forward for millions of patients in Europe. The market for pharmaceutical cannabis is the fastest growing market worldwide. In Canada, the industry grew from 170 million to a 30 billion industry within three years. We aim to provide cost efficient and custom tailored cannabinoid therapies to support a similar success story for the European markets. When future historians write a history of entrepreneurship, the market liberalization of pharmaceutical cannabis will get a separate chapter. Dozens of investors are waiting in line to be a part of this story.”

Niklas Kouparanis, Founder and CEO of Farmako: “This first step enables us to build a reliable distribution network in all European jurisdictions with a legal basis for pharmaceutical cannabis. The German is twice as big as the Canadian market, and additional European markets like the United Kingdom markets are opening up. We are in the unique position of reaping the full benefits of a second mover advantage: We adapt the smart moves of our predecessors and do not repeat their mistakes.”

Pharmacann Polska’s representative - Yuval Soiref, the Co-Founder, CEO and International Business Development: “This exclusive agreement is a great success and not only ensures stable supply of pharmaceutical cannabis, but also a beginning of research-based development of innovative cannabis strains for better and more targeted medical treatment. Thanks to our sophisticated growing systems and pharmaceutical-grade extraction, we are one of the very few players worldwide who are able to guarantee the highest quality cannabis in the largest amount ever seen in European history. Together with Farmako, we enter into an exclusive and promising partnership to move cannabinoid-based healthcare forward.” 

Farmako and Pharmacann Polska have agreed on a deep partnership in research and development. It focuses on the joint development of new custom-tailored cannabis strains, while using the full advantage of producing at a substantially lower cost in the eastern part of the EU. Kouparanis: “We will produce a higher quality medicine at a lower price than our Canadian competitors. The first pharmaceutical cannabis shipment is expected to be in German pharmacies by June 2019.” For the next four years, Pharmacann Polska will provide pharmaceutical Cannabis exclusively for Farmako. This finally ensures a stable supply for the German patients which Canadian suppliers could not guarantee in the past year. 

Germany will not be the only country to benefit from high-quality therapies with pharmaceutical cannabis. Kouparanis: "We will be active in every European jurisdiction that creates a legal basis. In the United Kingdom, Denmark and Luxembourg, pharmaceutical cannabis was also approved. Many more European countries will follow soon. We plan to become Europe's leading pharmaceutical cannabis company and to ensure security of supply in these countries as well. We guarantee that European cannabis for European patients is not only legal, but also affordable and available.”

Background to the pharmaceutical cannabis shortage in Europe

The current pharmaceutical cannabis shortages in Europe are a consequence of the legalization of cannabis for recreational use in Canada in October 2018. Canada and the Netherlands had been the most important suppliers of pharmaceutical Cannabis for German patients. One consequence was that German patients were often unable to redeem their medical prescriptions which jeopardizes sustainable therapies and damaged the reputation of existing market participants. Cultivation in Germany itself is uncertain and will be too little, too late. An invitation to tender for the domestic cultivation of pharmaceutical cannabis was initiated as early as 2017. However, it was overturned in 2018 by the Dusseldorf Higher Regional Court. A final decision is expected in April 2019. The first harvest is expected in 2021 at the earliest. Moreover, the total amount of this tender is 10.4 tonnes over four years. The total volume of the tender is only one fifth of the import agreement now closed by Farmako.

Aim of research and development

Sebastian Diemer, Managing Director of the holding company 'The Good Company': "This milestone enables us to help more patients reliably and better. Often, therapies with pharmaceutical cannabis have fewer side effects than the alternatives. In addition, they relieve the health system because they cost less."

Patrick Schmitt, Co-Founder and CSO: "Cannabinoids have not been part of pharmaceutical research for over 80 years. Neither the manufacturing, processing nor the pharmaceutical application has made any significant progress. We want to lead the catch-up. We already know that cannabinoids such as THC or CBD work better in many cases than current commercial drugs. Be it in severe pain, insomnia or nervous diseases or even in cancer treatment."

Dr. Lena Mueller, a physician specializing in clinical trials at Farmako, explains: "We are only just at the beginning of empirical, evidence-based research in medicine. Many patients will be relieved. They are finally certain that they can rely on pharmacies to switch to pharmaceutical cannabis therapy."

About Farmako GmbH

Farmako GmbH is a research-based pharmaceutical company based in Frankfurt. The company relies on the distribution of pharmaceutical cannabis and research in order to catch up on the research backlog in the field of pharmaceutical cannabis. Farmako plans to become a vertically integrated market leader in every European country in this market with the appropriate legal basis.

About PharmaCann Polska Sp. z o.o.

Pharmacann Polska Sp. z o.o. is an international pharmaceutical company that applies global standards in production of cannabis-based pharmaceutical raw materials. Using the Israeli and Canadian markets experience, our mission is to ensure the availability of products containing cannabinoids of natural origin while maintaining strictly controlled pharmaceutical quality and to disseminate knowledge about their medicinal use.


Press Contact:

Marcus Ewald
+49 176 22824218

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CESTPress release

Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be

Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio16.7.2019 10:52:00 CESTPress release

MANCHESTER, United Kingdom, July 16, 2019 (GLOBE NEWSWIRE) -- Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics. Specifically, Epistem aims to help customers define whether there are reasons to suspect that there may be human toxicity issues. This will allow better prioritisation of lead compounds, with customers able to make early decisions on whether to abandon, identify alternatives, or develop mitigation strategies for any drugs with human toxicity. Organoids are adult stem cell patient or animal derived structures. Organoids are genetically stable and maintain epithelial functionality in the laboratory. The expanding

Bombardier’s Multi-Award-Winning Global 7500 Jet Reaches New Heights in the Heart of the Swiss Alps15.7.2019 19:00:00 CESTPress release

Global 7500 aircraft is the most spacious purpose-built business jet to operate out of Gstaad’s Saanen airport in Switzerland, where it was on display earlier this month before flying to Dubai, performing another exceptional long-range mission Mission highlights the Global family’s advanced wing design, which enables them to access challenging airfields with short runways in hot temperatures and/or high altitude locations, giving passengers direct access to the heart of the Swiss Alps all year round The Aviation Week Grand Laureate Global 7500 aircraft, also recently recognized as Business Jet of the Year in Robb Report’s Best of the Best 2019, offers Bombardier’s signature smooth ride and a spaciousness that is unique among business jets Bombardier’s Challenger 350 aircraft, also recognized as the Best of the Best Super Mid-size Aircraft by Robb Report, joined the Global 7500 jet on display in Gstaad and achieved a speed record, reaching Malaga in 2 hours and 4 minutes MONTREAL, July

Brookfield Asset Management 2019 Second Quarter Results Conference Call and Webcast15.7.2019 18:27:00 CESTPress release

Date: Thursday, August 8, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, July 15, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2019 Second Quarter Conference Call & Webcast on Thursday, August 8, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 8258617) at approximately 10:50 a.m. The Conference Call will also b

Virtusa Achieves AWS Life Sciences Competency Status15.7.2019 16:01:00 CESTPress release

Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics. Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS.

LGC Capital, Ltd., announces Trichomed received its cultivation license from Health Canada for its new cannabis facility in Brownsburg, Quebec15.7.2019 15:28:00 CESTPress release

MONTREAL, July 15, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) LGC Capital Ltd. (“LGC” or the “Company”), announces that Health Canada, on July 12th, awarded Trichomed Corporation (Trichomed), its long awaited license to cultivate cannabis seeds and plants at its newly constructed facility in Brownsburg, Quebec. As per the terms of its agreement with Trichomed, LGC is, now entitled to convert the first ranking secured loan it provided to Trichomed in December 2017 into a 49% direct equity interest, and a five percent (5%) royalty of Trichomed’s net sales of cannabis and cannabis-related prodcuts which covers actual sales less any arm’s length third-party discounts, merchandise returns and rebates. In addition as per the agreement, LGC is entitled to representation on Trichomed’s board. For further information, please contact: John McMullen, President Tel: (416) 803-0698 Mark Shinners, Chief Financial Officer Tel: +44 7827 960971 mark@lgc-ca